In the present study, we found that the intestinal FXR activation mediated FGF15 is increased in NASH mice upon BBR treatment, and the binding of FGF15 with liver-specific receptor FGFR4 may contribute to the anti-steatosis and anti-inflammatory properties of BBR. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.